2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVOX 2倍做多NVO ETF-Defiance

盘前交易 02-24 09:18:22 EST

11.56

-5.63

-32.75%

盘前10.78

-0.78-6.74%

09:17 EST

最高12.61	最低11.34	成交量450.14万
今开11.92	昨收17.19	日振幅7.36%
总市值3,131万	流通市值3,131万	总股本270.81万
成交额5,363万	换手率166.22%	流通股本270.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":11.56,"timestamp":1771880400000,"preClose":17.19,"halted":0,"volume":4501400,"hourTrading":{"tag":"盘前","latestPrice":10.7807,"preClose":11.56,"latestTime":"09:17 EST","volume":144041,"amount":1579590.480496,"timestamp":1771942675848,"change":-0.7793,"changeRate":-0.067413,"amplitude":0.027682},"delay":0,"changeRate":-0.3275159976730658,"floatShares":2708101,"shares":2708101,"eps":0,"marketStatus":"盘前交易","change":-5.63,"latestTime":"02-24 09:18:22 EST","open":11.92,"high":12.605,"low":11.34,"amount":53633739.8628,"amplitude":0.073589,"askPrice":10.8,"askSize":1740,"bidPrice":10.77,"bidSize":1620,"shortable":0,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":11.56,"sharesOutstanding":2708101,"nav":17.22,"aum":46633499.22,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":10.7807,"preClose":11.56,"latestTime":"09:17 EST","volume":144041,"amount":1579590.480496,"timestamp":1771942675848,"change":-0.7793,"changeRate":-0.067413,"amplitude":0.027682},"postHourTrading":{"tag":"盘后","latestPrice":11.69,"preClose":11.56,"latestTime":"19:56 EST","volume":91180,"amount":1059065.8951,"timestamp":1771894619625,"change":0.13,"changeRate":0.011246,"amplitude":0.018166},"volumeRatio":17.00903989660571,"impliedVol":0.6716,"impliedVolPercentile":0.3454},"requestUrl":"/m/hq/s/NVOX","defaultTab":"news","newsList":[{"id":"2613712854","title":"价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613712854?lang=zh_cn&edition=full","pubTime":"2026-02-24 21:31","pubTimestamp":1771939893,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变化。Millar强调，两次降价相互独立，并无关联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BK4W5L77.USD","BK4533","LU2491050071.SGD","LU0210536198.USD","LU2168563687.JPY","ELIL","LU2023250504.SGD","LU2471134952.CNY","LLYZ","LU2089284900.SGD","LU2271345857.HKD","LU2552382058.USD","LU0058720904.USD","LU0114720955.EUR","IE0009355771.USD","IE0004445239.USD","LU1023059063.AUD","LU0820562030.AUD","NVOX","LU2168564222.USD","LU2456880835.USD","LU0417517546.SGD","LU1551013342.USD","LU1983299246.USD","LU0238689110.USD","BK4007","LU0289739699.SGD","LU1061106388.HKD","NVO","ELIS","NVOH","LLY","IE00BJJMRZ35.SGD","LU0432979614.USD","LU1917777945.USD","BK4599","LU0106261372.USD","LU2237443549.SGD","LLII","LU2168564149.EUR","LU0203202063.USD","LU1720051108.HKD","LU2602419157.SGD","LU0320765992.SGD","LU1145028129.USD","LU2756315318.SGD","IE00BK4W5M84.HKD","LLYX","SG9999013999.USD","LU2168564065.EUR"],"gpt_icon":1},{"id":"2613171180","title":"礼来盘前下跌 诺和诺德将下调Ozempic和Wegovy在美国的价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2613171180","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613171180?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:53","pubTimestamp":1771937580,"startTime":"0","endTime":"0","summary":"礼来股价在盘前交易中一度迅速下跌4.1%，此前据《华尔街曰报》报道，竞争对手诺和诺德计划将Ozempic和Wegovy在美国市场的定价下调至多50%。\n　　《华尔街曰报》报道，上述糖尿病及减肥治疗药物自2027年1月1日起，每月定价均将调整为675美元\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-24/doc-inhnxnuf1949059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2471134952.CNY","IE00BJJMRX11.SGD","LU0097036916.USD","LU0640476718.USD","LU2023251221.USD","BK4532","LU1064131342.USD","SGXZ31699556.SGD","LU2324357040.USD","IE00BK4W5M84.HKD","LU2236285917.USD","LU0158827781.USD","IE0002141913.USD","LU0203201768.USD","SG9999001176.SGD","SGXZ99366536.SGD","LU1917777945.USD","IE00B7KXQ091.USD","LU0943347566.SGD","LU2111349929.HKD","SGXZ51526630.SGD","LU2264538146.SGD","IE00BJT1NW94.SGD","LU1232071149.USD","LU0096364046.USD","LU2471134523.USD","IE00B1BXHZ80.USD","NVO","LU2750360641.GBP","IE00B4R5TH58.HKD","LU0820561909.HKD","IE0001KFT4U8.USD","LU1127390331.HKD","IE00BKPKM429.USD","LU0109394709.USD","LU0471298777.SGD","LU0256863902.USD","LU1323610961.USD","LU2471134879.HKD","IE00BK4W5L77.USD","LU1291159041.SGD","BK4007","LU2237443549.SGD","BK4585","LU1548497426.USD","LU2896262040.SGD","LU2491049909.HKD","LU1868836914.USD","LU0823416689.USD","LU2237443895.HKD","LU2552382215.SGD","LU0432979614.USD","IE00BKDWB100.SGD","SG9999015945.SGD","SG9999015986.USD","SGXZ81514606.USD","LU0320765059.SGD","LU1720051017.SGD","LU1280957306.USD","BK4599","LU0689472784.USD","LU2462157665.USD","LU2023250330.USD","LLY","LU0079474960.USD","SG9999013999.USD","LU1868836757.USD","LU1814569148.SGD","LU1366192091.USD","IE00BZ1G4Q59.USD","LU1868836591.USD","LU0787776722.HKD","LU2756315318.SGD","BK4534","LU1974910355.USD","IE00B4JS1V06.HKD","LU0964807845.USD","IE0009355771.USD","LU1093756168.USD","LU2746668461.USD","LU2237443622.USD","LU1035775433.USD","LU0154236417.USD","SG9999015978.USD","LU2468319806.SGD","LU2168564149.EUR","SGXZ57979304.SGD","GB00BDT5M118.USD","SG9999014880.SGD","LU2211815571.USD","LU0203202063.USD","LLYX","IE0004445015.USD","IE00BFSS7M15.SGD","LU0238689110.USD","LU2168564495.EUR","LU2361044865.SGD","BK4581","SG9999014898.SGD","LU2023250504.SGD","LU0114720955.EUR","LU2746668974.SGD","BK4588","LU0672654240.SGD","LU0106261372.USD","LU0058720904.USD","LU0882574139.USD","LU1145028129.USD","LU1868837136.USD","LU2461242641.AUD","LU2063271972.USD","LU0466842654.USD","LU2168564222.USD","LU2087625088.SGD","NVOH","LU2089284900.SGD","LU0786609619.USD","LU2237443978.SGD","LU2112291526.USD","LU2168563687.JPY","LU2552382132.HKD","LU1804176565.USD","SG9999014914.USD","SG9999018865.SGD","LU2456880835.USD","LU0061475181.USD","LU2361044949.HKD","LU0109391861.USD","IE00BKVL7J92.USD","IE00BN29S564.USD","LU0266013472.USD","LU2360106947.USD","SG9999014906.USD","LU2089984988.USD","SG9999018857.SGD","LU2213496289.HKD","LU2417539215.USD","LU2106854487.HKD","LU2361045086.USD","IE00BJJMRY28.SGD","LU1057294990.SGD","IE00BFSS8Q28.SGD","LU0417517546.SGD","LU0316494557.USD","IE00BFTCPJ56.SGD","LU2089283258.USD","LU1623119135.USD","LU2491050071.SGD","LU0122379950.USD","LU0158827948.USD","LU0225283273.USD","LU0354030511.USD","LU2491050154.USD","LU1551013342.USD","LU0353189763.USD","LU0256863811.USD","IE00BJLML261.HKD","LU2756315664.SGD","LU0820561818.USD","LU0006306889.USD","LU2237443382.USD","LU0323591593.USD","LU2552382058.USD","LU0320765992.SGD","LU0889565916.HKD","LU1989771016.USD","LU0683600562.USD","LU2471134796.USD","NVOX","LU1023059063.AUD","LU1093756325.SGD","SG9999015952.SGD","IE00B1XK9C88.USD","LU0708995401.HKD","LU1712237335.SGD","LU1551013425.SGD","IE0005OL40V9.USD","LU0882574055.USD","LU1267930730.SGD","LU2602419157.SGD","LU2265009873.SGD","IE00B2B36J28.USD","LU2168564065.EUR","LU2237443465.HKD","ELIL","LU1988902786.USD","LU0289739699.SGD","LU2357305700.SGD","LU1868837300.USD","LU0385154629.USD","ELIS","LU0456855351.SGD","IE00BWXC8680.SGD","LLII","IE00B775H168.HKD","LU2750360997.AUD","LU1069344957.HKD","LU0234572021.USD","LU0820562030.AUD","LU0471298694.HKD","LU2108987350.USD","SG9999001176.USD","SG9999017495.SGD","LU2271345857.HKD","LU1983299246.USD","LU0823434740.USD","LU2028103732.USD","LU0354030438.USD","LU1720051108.HKD","LU1061106388.HKD","LLYZ","LU0198837287.USD","IE0004445239.USD","LU0094547139.USD","LU1629891620.HKD","LU0210536198.USD","BK4516","IE00BJJMRZ35.SGD","BK4533","LU0823434583.USD","LU0353189680.USD","LU2237438978.USD"],"gpt_icon":0},{"id":"2613711325","title":"诺和诺德美股盘前下跌3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711325","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613711325?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:43","pubTimestamp":1771936992,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月24日，诺和诺德美股盘前下跌3%，公司将司美格鲁肽（Wegovy）在美售价下调50%，至每月675美元。每日经济新闻","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224204542a4c31745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224204542a4c31745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4535","IWN","IE00BZ1G4Q59.USD","LU1093756168.USD","SRTY","TWM","LU1093756325.SGD","TNA","BK4532","BK4585","IWO","BK4534","BK4599","UWM","NVOH","MNQmain","BK4550","TZA","NVO","BK4007","RWM","NVOX","BK4581","LU0154236417.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2613584719","title":"诺和诺德将司美格鲁肽(Wegovy®)在美售价下调50%，至每月675美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2613584719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613584719?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:35","pubTimestamp":1771936542,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","NVOH","NVOX","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","BK4585","BK4007","BK4599"],"gpt_icon":0},{"id":"2613271339","title":"诺和诺德和联邦生物科技的新减肥药帮助患者减轻体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2613271339","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613271339?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:35","pubTimestamp":1771932900,"startTime":"0","endTime":"0","summary":"诺和诺德和联邦生物科技表示，二者联合开发的一款实验性肥胖症药物在中国的一项中期临床试验中帮助患者减轻了体重。　　诺和诺德和联邦生物科技的母公司联邦制药国际控股周二表示，在这项中国研究中，名为UBT251的药物在给药24周后，使患者平均体重减轻了最高19.7%。　　两家公司正根据去年3月签署的一项价值最高20亿美元的协议共同开发该药物，这是诺和诺德为补充其药物新产品永续规划而达成的数项交易之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-24/doc-inhnxnuh8710404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVO","BK4585","LU1093756168.USD","01084","BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVOX","LU1093756325.SGD","BK4532","NVOH","BK4007","LU0154236417.USD","BK4599"],"gpt_icon":1},{"id":"2613431767","title":"德银：将诺和诺德目标价下调至275丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2613431767","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613431767?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:16","pubTimestamp":1771917363,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4588","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","BK4007","BK4599","NVOX"],"gpt_icon":0},{"id":"2613007764","title":"花旗：将诺和诺德目标价调至309丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2613007764","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613007764?lang=zh_cn&edition=full","pubTime":"2026-02-24 14:30","pubTimestamp":1771914618,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨花旗集团将诺和诺德目标价从340丹麦克朗下调至309丹麦克朗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224143338a4c1bd7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224143338a4c1bd7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","LU0130102774.USD","LU0106831901.USD","LU1506573853.SGD","LU1267930227.SGD","BK4566","BK4588","LU0098860793.USD","BK4559","LU1093756168.USD","LU2125154935.USD","LU0980610538.SGD","LU1201861249.SGD","LU0052756011.USD","LU0170899867.USD","LU1668664300.SGD","NVOH","LU1244550221.USD","LU0072461881.USD","LU1791807156.HKD","LU0130517989.USD","LU2360032135.SGD","LU2456880835.USD","LU0128525689.USD","LU0314106906.USD","BK4532","LU0310800965.SGD","IE00BKVL7J92.USD","BK4207","LU2125154778.USD","LU1244550577.SGD","BK4534","BK4585","LU1244550494.USD","BK4599","BK4504","LU0154236417.USD","NVO","IE00BSNM7G36.USD","LU2462157665.USD","LU1162221912.USD","LU0648001328.SGD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU2417539215.USD","BK4007","LU0162691827.USD","NVOX","LU0320765646.SGD","LU0477156953.USD","LU1366192091.USD"],"gpt_icon":0},{"id":"2613769464","title":"暴跌超16%！诺和诺德股价跌回“司美格鲁肽前时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=2613769464","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613769464?lang=zh_cn&edition=full","pubTime":"2026-02-24 13:03","pubTimestamp":1771909380,"startTime":"0","endTime":"0","summary":"2026年对于诺和诺德而言是关键之年。该公司的司美格鲁肽市场份额正面临以礼来为首的多家竞争对手的挤压。在中国市场，司美格鲁肽的核心分子专利也将面临到期。　　诺和诺德当天股价收盘暴跌超过16%，不仅创下2021年6月以来新低，也抹去了上一代减重药司美格鲁肽上市以来的所有涨幅。届时该药物与已经获批的诺和诺德口服司美格鲁肽减重药的竞争将进一步加剧。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwvwu3187198.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwvwu3187198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVOH","IE00BKVL7J92.USD","BK4588","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","BK4007","NVO","NVOX","BK4585","LU1093756168.USD","LU1093756325.SGD","BK4599"],"gpt_icon":1},{"id":"2613535766","title":"小摩下调诺和诺德欧股评级至“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2613535766","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613535766?lang=zh_cn&edition=full","pubTime":"2026-02-24 12:35","pubTimestamp":1771907740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4588","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"1166910157","title":"ETF日报｜2倍做多白银ETF涨超10%；2倍做多诺和诺德ETF暴跌近33%；贵金属走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1166910157","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166910157?lang=zh_cn&edition=full","pubTime":"2026-02-24 09:20","pubTimestamp":1771896000,"startTime":"0","endTime":"0","summary":"美股ETF跌幅Top5$2倍做多NVO ETF-Defiance$下跌32.75%。该ETF两倍做多单股NVO，所跟踪制药公司诺和诺德股价走低，杠杆多头承压同步放大跌幅。$2倍做多DDOG ETF-Tradr$下跌22.39%。该ETF两倍做多替代加密资产组合，相关加密资产价格走弱拖累基金表现并放大波动。大宗商品ETF涨幅 Top 5$2倍做多白银ETF-ProShares$上涨10.07%。该ETF两倍做多黄金矿业公司股，金价走强提升矿业股盈利预期，板块整体上行推升基金。$二倍做多能源ETF-Direxion$上涨1.04%。该ETF广泛覆盖美债，债券市场整体上行促使基金走高。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"热榜No.10 · 诺和诺德新一代减肥药试验效果不及礼来引发股价大跌15%以上","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FAZ","GOVT","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","BEG","NVOH","NVOX","XME","XLP","SPTI","SPTL","BK4550","BK4547","ZSL","DGP","BK4588","NVO","SLV","DOGD","MDBX","UGL","DXD","SKF","LU1093756168.USD","BK4599","XLV","ERX","BK4585","BK4535","SIVR","BK4532","PSLV","AGQ","BK4007","TZA","SPXU","FDN","SDOW","TLT","SQQQ","IEF","SIL","NUGT"],"gpt_icon":0},{"id":"2613275783","title":"药企扎堆减肥药赛道，千亿美元赛道格局将生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2613275783","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613275783?lang=zh_cn&edition=full","pubTime":"2026-02-24 09:19","pubTimestamp":1771895983,"startTime":"0","endTime":"0","summary":"据相关预测，到 2030 年，全球减肥药市场价值有望突破 1500 亿美元。除了礼来，2026年以来还有大批医药企业在减肥药方面加速布局。如1月30日，石药集团公告称，已与阿斯利康签署战略研发合作与授权协议。本次合作，潜在总金额高达185亿美元。未来，行业竞争预计会愈演愈烈，企业需构建差异化技术壁垒、强化商业化能力、拓展适应症边界，才能在千亿美元赛道中脱颖而出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224092341a71795ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224092341a71795ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4532","LU0154236417.USD","LU1093756325.SGD","NVOX","NVOH","BK4007","LLY","LU1093756168.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4599","NVO","BK4585"],"gpt_icon":1},{"id":"2613075952","title":"股价暴跌超16%！诺和诺德新药临床失利！礼来股价再创新高！Zepbound升级巩固优势、一支用整月！","url":"https://stock-news.laohu8.com/highlight/detail?id=2613075952","media":"美股IPO","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613075952?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:03","pubTimestamp":1771891419,"startTime":"0","endTime":"0","summary":"礼来周一推出了其重磅减肥药Zepbound的一种新剂型。媒体称，此次发布正值礼来努力巩固Zepbound早期成功之际。自2023年底上市以来，Zepbound需求激增。礼来在声明中表示，美国食品药品监督管理局已批准扩大Zepbound的标签适应范围，将多剂量装置纳入其中。替尔泊肽以Mounjaro之名用于治疗2型糖尿病，以Zepbound之名用于治疗肥胖。过去一年，诺和诺德股价已累计下跌超过一半。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224081135a4c0712f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224081135a4c0712f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0456855351.SGD","LU1232071149.USD","LU0882574139.USD","LU0820561909.HKD","LU2357305700.SGD","LU0006306889.USD","LU2063271972.USD","IE0004445015.USD","IE00B4JS1V06.HKD","SG9999014914.USD","IE0009355771.USD","LU0320765992.SGD","LU2456880835.USD","LU2211815571.USD","IE00BKVL7J92.USD","LU1057294990.SGD","LU0354030438.USD","LU0097036916.USD","LU0689472784.USD","LU0353189680.USD","LU0353189763.USD","LU2491050154.USD","SG9999018857.SGD","LU1093756168.USD","LU2360106947.USD","LU2461242641.AUD","LU2089284900.SGD","LU0943347566.SGD","BK4581","LU1814569148.SGD","LU0820561818.USD","IE00BWXC8680.SGD","LU2023251221.USD","SG9999001176.SGD","LU1917777945.USD","IE0005OL40V9.USD","LU2168564065.EUR","LU2361044865.SGD","LU1720051108.HKD","IE00BK4W5M84.HKD","LU0820562030.AUD","IE0002141913.USD","LU2417539215.USD","IE00B775H168.HKD","LU1988902786.USD","LU0158827781.USD","LU0234572021.USD","LU2265009873.SGD","LU1989771016.USD","SGXZ31699556.SGD","LU1064131342.USD","LU2168564222.USD","LU2264538146.SGD","LU0672654240.SGD","BK4007","IE00BKDWB100.SGD","LU0203202063.USD","SG9999001176.USD","LU0640476718.USD","LU1629891620.HKD","SGXZ99366536.SGD","BK4599","LU0385154629.USD","LLYZ","IE00B4R5TH58.HKD","BK4532","LU0158827948.USD","LU0964807845.USD","LU2237438978.USD","LU1291159041.SGD","LU0210536198.USD","LU2112291526.USD","SG9999015952.SGD","LU1712237335.SGD","IE00B1XK9C88.USD","SG9999014906.USD","LU2237443978.SGD","LU0109394709.USD","LU0889565916.HKD","IE00BN29S564.USD","LU0471298777.SGD","IE00BK4W5L77.USD","LU1323610961.USD","LU1804176565.USD","LU2468319806.SGD","NVOX","SGXZ81514606.USD","LU1868836757.USD","LU0256863811.USD","LU1366192091.USD","LU0316494557.USD","IE0001KFT4U8.USD","LU0466842654.USD","BK4585","LU0354030511.USD","LU0320765059.SGD","LU0787776722.HKD","LU1868836591.USD","LU2028103732.USD","LU2168564495.EUR","SG9999015986.USD","LU1035775433.USD","SG9999015945.SGD","LU0823434583.USD","LU0708995401.HKD","LU2552382215.SGD","LU2237443465.HKD","SG9999013999.USD","IE00B1BXHZ80.USD","ELIL","LU0238689110.USD","LU1061106388.HKD","LU2089984988.USD","NVO","SG9999015978.USD","LU0058720904.USD","LU0079474960.USD","SG9999018865.SGD","LU2168563687.JPY","LU1093756325.SGD","LU1023059063.AUD","LU0417517546.SGD","LU2168564149.EUR","LU2471134796.USD","IE00BFSS8Q28.SGD","LU2237443622.USD","IE00BZ1G4Q59.USD","LU2111349929.HKD","LU1551013425.SGD","SGXZ51526630.SGD","LU0289739699.SGD","LU2106854487.HKD","LU2361045086.USD","LU1868837300.USD","LU2750360641.GBP","LU1974910355.USD","IE0004445239.USD","LU0114720955.EUR","IE00BFSS7M15.SGD","LU0122379950.USD","BK4533","SG9999017495.SGD","IE00BJLML261.HKD","LU2756315318.SGD","LLY","LU2491050071.SGD","LU0823434740.USD","LU1069344957.HKD","LU0154236417.USD","SGXZ57979304.SGD","IE00BJJMRX11.SGD","LU2108987350.USD","LU0106261372.USD","IE00BJJMRY28.SGD","LU1267930730.SGD","LU1868837136.USD","LU2236285917.USD","GB00BDT5M118.USD","IE00B7KXQ091.USD","LU0266013472.USD","LU0256863902.USD","LU2237443895.HKD","ELIS","LU2756315664.SGD","LU0096364046.USD","LLYX","LU0323591593.USD","NVOH","SG9999014898.SGD","LU2087625088.SGD","LU2746668461.USD","LU2471134523.USD","LU0109391861.USD","IE00BJT1NW94.SGD","LU2271345857.HKD","LU1983299246.USD","LU2896262040.SGD","LU0094547139.USD","LU2750360997.AUD","LLII","SG9999014880.SGD","BK4588","LU2471134879.HKD","LU1868836914.USD","IE00B2B36J28.USD","LU1551013342.USD","LU2746668974.SGD","LU1145028129.USD","LU0786609619.USD","LU2602419157.SGD","LU0823416689.USD","LU2237443382.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU2552382132.HKD","LU1720051017.SGD","LU2089283258.USD","LU0225283273.USD","LU1623119135.USD","LU2023250504.SGD","LU0198837287.USD","LU2471134952.CNY","BK4516","LU2491049909.HKD","LU1548497426.USD","LU0203201768.USD","BK4534","LU2462157665.USD","IE00BKPKM429.USD","LU0471298694.HKD","LU0683600562.USD","LU0882574055.USD","LU1127390331.HKD","LU2237443549.SGD","LU2361044949.HKD","LU2023250330.USD","LU1280957306.USD","LU2213496289.HKD","LU2324357040.USD","LU2552382058.USD"],"gpt_icon":1},{"id":"1132858426","title":"诺和诺德股价暴跌逾16%！其减肥药CagriSema实验效果不及礼来畅销药Zepbound","url":"https://stock-news.laohu8.com/highlight/detail?id=1132858426","media":"券商中国","labels":["productRelease","movement"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132858426?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:15","pubTimestamp":1771884948,"startTime":"0","endTime":"0","summary":"减肥药巨头诺和诺德股价暴跌，截至全天收盘，跌超16%。消息面上，诺和诺德下一代减肥药物CagriSema在一项试验中达到的减重效果不如其竞争对手礼来的畅销药物。诺和诺德发布声明称，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。诺和诺德宣布CagriSema对比替尔泊肽的减重III期REDEFINE 4研究未达到主要终点。诺和诺德表示，正在探索更多试验方案来测试CagriSema，包括更高剂量组合方案。受此影响，其美股股价单日暴跌超14%。","market":"us","thumbnail":"https://static.tigerbbs.com/2b0d0fb2abb1fe3ab32e941108eea5b9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2b0d0fb2abb1fe3ab32e941108eea5b9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"诺和诺德股价暴跌逾16%！其减肥药CagriSema实验效果不及礼来畅销药Zepbound","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","NVOX","NVO"],"gpt_icon":0},{"id":"2613873074","title":"Zepbound在与诺和诺德的实验性GLP-1药物的直接对比试验中胜出Zepbound beats Novo Nordisk’s experimental GLP-1 in head-to-head trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2613873074","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613873074?lang=zh_cn&edition=full","pubTime":"2026-02-24 04:17","pubTimestamp":1771877820,"startTime":"0","endTime":"0","summary":"A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss.诺和诺德领导的一项研究比较了其用于治疗肥胖的GLP-1候选药物CagriSema，发现礼来公司的Zepbound带来了更大的减重效果。The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema or Zepbound. After 84 weeks, the CagriSema group achieved a 20.2% reduction in weight, compared to the 23.6% weight loss with Zepbound.开放标签、头对头试验分析了每周接受CagriSema或Zepbound注射的成年人的平均减重情况。Novo Nordisk诺和诺德announced宣布the phase 3 trial results Feb. 23. The trial included 809 adults with obesity and at least one comorbidity, according to the Denmark-based drugmaker.2月23日公布了第三阶段试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224053312a4c00f97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224053312a4c00f97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","NVO","NVOH","LLY","LU0154236417.USD","BK4588","BK4144","LU1093756168.USD","BK4532","BK4585","BK4599","BK4590","NVOX","BK4007"],"gpt_icon":1},{"id":"2613735996","title":"分析师：诺和诺德CagriSema受挫，或使投资者焦点转向并购战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2613735996","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613735996?lang=zh_cn&edition=full","pubTime":"2026-02-24 00:36","pubTimestamp":1771864560,"startTime":"0","endTime":"0","summary":"诺和诺德的新一代减肥药 CagriSema 在头对头临床试验中，效果不及礼来的 Zepbound。这对这家丹麦药企试图重夺减肥药市场领先地位的努力构成新一轮打击。　　“我们实在找不到任何理由，在 CagriSema 获批上市后，医生会给患者开这款药而不是礼来的替尔泊肽。”　　“尽管我们仍认为 CagriSema 能够获批，但今日 RD4 试验结果意味着，面对疗效更好、耐受性更佳的竞品，其市场推广将举步维艰，诺和诺德除了价格外几乎没有其他竞争手段。”","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-24/doc-inhnvukz2596714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","LU0154236417.USD","BK4007","NVO","BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","LU1093756168.USD","BK4588","LU1093756325.SGD","BK4599"],"gpt_icon":1},{"id":"2613801735","title":"大跌10%！诺和诺德CagriSema头对头替尔泊肽3期临床失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2613801735","media":"生物药大时代","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613801735?lang=zh_cn&edition=full","pubTime":"2026-02-24 00:01","pubTimestamp":1771862504,"startTime":"0","endTime":"0","summary":"2月23日，诺和诺德宣布CagriSema对比替尔泊肽的减重III期REDEFINE 4研究未达到主要终点。受此消息影响，诺和诺德股价大跌15%。若按治疗方案评估，治疗84周后，CagriSema组和替尔泊肽组患者的体重分别减轻了20.2%和23.6%。本研究未能达到其主要终点，即在 84 周时证明 CagriSema 在体重下降方面相较于 tirzepatide 具有非劣效性。在本研究中，CagriSema 显示出良好的安全性和耐受性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224000516a7166405&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224000516a7166405&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","NVO","BK4599","LU0154236417.USD","LU1093756168.USD","BK4585","NVOX","LU1093756325.SGD","BK4007","BK4588","NVOH","BK4532","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2613802567","title":"诺和诺德股价重挫15.50% 市值跌276.18亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613802567","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613802567?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:31","pubTimestamp":1771857065,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时31分，诺和诺德股票出现异动，股价快速下跌15.50%。截至发稿，该股报40.07美元/股，成交量1906.35万股，换手率0.43%，振幅0.84%。最近的财报数据显示，该股实现营业收入467.36亿美元，净利润154.90亿美元，每股收益3.49美元，毛利375.48亿美元，市盈率11.06倍。诺和诺德股票所在的制药行业中，整体涨幅为1.81%。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223105a716318a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223105a716318a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK4585","NVOH","BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","NVOX","BK4599","LU1093756168.USD","LU0154236417.USD","BK4588"],"gpt_icon":1},{"id":"2613784401","title":"利空突袭！刚刚，直线大跳水！欧洲巨头，崩了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784401","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613784401?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:54","pubTimestamp":1771851283,"startTime":"0","endTime":"0","summary":"欧洲减肥药巨头突传利空。今日，在欧洲交易时段，减肥药巨头诺和诺德股价大幅跳水，一度暴跌超15%，在美股盘前交易中，诺和诺德股价亦暴跌超14%。消息面上，该公司的下一代减肥药物CagriSema的实验效果不及美国礼来公司的Zepbound。值得一提的是，今年以来，诺和诺德爆雷不断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602233652006715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","BK4585","LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVOX","LU1093756325.SGD","BK4532","NVOH","BK4007","LU0154236417.USD","BK4599"],"gpt_icon":1},{"id":"2613564757","title":"重磅新药III期临床失败，诺和诺德大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2613564757","media":"药圈观察局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613564757?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:03","pubTimestamp":1771848180,"startTime":"0","endTime":"0","summary":"消息一出，诺和诺德美股盘前股价应声大跌约11%，而礼来则上涨约3.4%。2022年，诺和诺德直接跳过肥胖症II期试验，启动了CagriSema用于肥胖症的III期临床研究REDEFINE 1。早在进入III期开发时，诺和诺德对外给出的目标是该复方疗法至少能够减重25%，这一数字几乎与减肥手术效果相媲美。结果公布当日，诺和诺德股价大跌，市值一天内缩水约1250亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224075739a4c06641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224075739a4c06641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4532","IE00BZ1G4Q59.USD","NVOH","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","NVO","BK4599","NVOX","LU1093756168.USD","BK4585","BK4134","BK4588"],"gpt_icon":1},{"id":"2613786145","title":"诺和诺德(NVO)盘前跌超15% 旗下CagriSema在试验中效果不及礼来Zepbound","url":"https://stock-news.laohu8.com/highlight/detail?id=2613786145","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613786145?lang=zh_cn&edition=full","pubTime":"2026-02-23 19:03","pubTimestamp":1771844639,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前跌超15%，截至发稿，报40.09美元。消息面上，诺和诺德下一代减肥药物CagriSema在一项试验中达到的减重效果不如同业美国礼来公司的畅销药物。诺和诺德今日发表声明指，接受标准剂量实验药物CagriSema治疗的受试者在84周后体重减轻了20.2%。相比之下，礼来的tirzepatide减重效果为23.6%。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297399","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2168564065.EUR","SG9999014906.USD","IE00BWXC8680.SGD","LU0385154629.USD","LU2491049909.HKD","LU0234572021.USD","IE00B4R5TH58.HKD","LU0820562030.AUD","LU1720051017.SGD","LU2236285917.USD","LU2168564222.USD","LU1623119135.USD","LU1291159041.SGD","LU0820561909.HKD","IE00BZ1G4Q59.USD","LU1093756168.USD","IE00BJJMRX11.SGD","IE00BKPKM429.USD","LU0203201768.USD","LU0456855351.SGD","IE0004445015.USD","LU0889565916.HKD","BK4532","IE00B2B36J28.USD","LU0787776722.HKD","LU2471134796.USD","LU0238689110.USD","LU2237438978.USD","LU0471298694.HKD","IE00B4JS1V06.HKD","LU2112291526.USD","LU2361044865.SGD","NVOH","LU0203202063.USD","LU0266013472.USD","LU2357305700.SGD","LU2108987350.USD","LU0823434583.USD","SG9999018857.SGD","SGXZ57979304.SGD","LU2471134879.HKD","SGXZ51526630.SGD","LU0820561818.USD","LU0154236417.USD","IE00BKDWB100.SGD","LU2265009873.SGD","LU1061106388.HKD","LU2063271972.USD","LU0210536198.USD","LU0417517546.SGD","LU2211815571.USD","LU2471134523.USD","IE0005OL40V9.USD","LU1551013342.USD","LU2456880835.USD","LU2089284900.SGD","LU2271345857.HKD","LU0640476718.USD","IE0004445239.USD","LU1989771016.USD","LU1868837136.USD","BK4533","SGXZ99366536.SGD","LU2264538146.SGD","LU2360106947.USD","SGXZ31699556.SGD","LU0158827948.USD","SG9999013999.USD","LU1323610961.USD","LLII","LU0058720904.USD","SG9999001176.USD","IE00BFSS7M15.SGD","LU2462157665.USD","LU0354030438.USD","LU0061475181.USD","LU0823434740.USD","IE00BJLML261.HKD","SG9999018865.SGD","LU2746668461.USD","LU0823416689.USD","IE00BK4W5M84.HKD","BK4534","LU0683600562.USD","LU0109391861.USD","LU2461242641.AUD","LU0158827781.USD","LU1069344957.HKD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU0882574055.USD","LU2750360997.AUD","LU2602419157.SGD","LU1145028129.USD","LU2111349929.HKD","LU1712237335.SGD","BK4581","LU2491050154.USD","LU2237443978.SGD","LU0006306889.USD","ELIS","LU0256863902.USD","SG9999001176.SGD","LU2756315318.SGD","LU1023059063.AUD","LU2087625088.SGD","LU0289739699.SGD","SG9999015986.USD","LU2237443382.USD","LU2552382058.USD","LU0109394709.USD","LU2896262040.SGD","LU2756315664.SGD","LU0096364046.USD","LU2168563687.JPY","LU0323591593.USD","LU1035775433.USD","LU1983299246.USD","LU1868836757.USD","LU0466842654.USD","SG9999014880.SGD","SG9999014914.USD","SG9999017495.SGD","LU2237443465.HKD","IE00BFSS8Q28.SGD","LU0316494557.USD","GB00BDT5M118.USD","LU0708995401.HKD","LU1064131342.USD","LU2168564495.EUR","LU1548497426.USD","LU1814569148.SGD","LU1366192091.USD","LU0882574139.USD","LU1551013425.SGD","IE0009355771.USD","LU2750360641.GBP","SG9999014898.SGD","LU2552382215.SGD","ELIL","LU0122379950.USD","LU1868837300.USD","LU2237443895.HKD","LU1267930730.SGD","LU2417539215.USD","LU0672654240.SGD","LU2468319806.SGD","SG9999015945.SGD","NVO","LU2023250504.SGD","LU2491050071.SGD","IE00BJJMRZ35.SGD","LU1720051108.HKD","IE00BN29S564.USD","LU0320765992.SGD","LU0198837287.USD","LU1232071149.USD","IE00BKVL7J92.USD","LU1974910355.USD","LU1629891620.HKD","BK4588","SG9999015978.USD","LU0354030511.USD","LU0079474960.USD","LU2746668974.SGD","LU0114720955.EUR","LU2023251221.USD","LU2552382132.HKD","LU0094547139.USD","LU0097036916.USD","LU2361045086.USD","LU2471134952.CNY","IE0002141913.USD","LU0353189680.USD","LU0786609619.USD","LU0943347566.SGD","LU2028103732.USD","BK4516","LLYZ","LU1988902786.USD","IE00B775H168.HKD","LU1804176565.USD","LU0964807845.USD","IE00B1XK9C88.USD","LU1093756325.SGD","LU0106261372.USD","IE00BK4W5L77.USD","LU2237443549.SGD","LU2089984988.USD","LU0225283273.USD","LU0256863811.USD","BK4585","LU1917777945.USD","LU1127390331.HKD","IE00BJT1NW94.SGD","LU0320765059.SGD","LU2361044949.HKD","BK4599","LU1868836591.USD","LU1868836914.USD","LU2237443622.USD","LLYX","SGXZ81514606.USD","IE00B7KXQ091.USD","LU0689472784.USD","LU2023250330.USD","LU2324357040.USD","SG9999015952.SGD","IE0001KFT4U8.USD","LU0353189763.USD","LU2089283258.USD","LU2168564149.EUR","BK4007","LU1280957306.USD","NVOX","IE00BFTCPJ56.SGD","IE00BJJMRY28.SGD","LU2106854487.HKD","LU0471298777.SGD","LU0432979614.USD","LU2213496289.HKD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.3884},{"period":"1month","weight":-0.6361},{"period":"3month","weight":-0.4004},{"period":"6month","weight":-0.6147},{"period":"1year","weight":-0.8762},{"period":"ytd","weight":-0.4719}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"2倍做多NVO ETF-Defiance","nameEN":"Defiance Daily Target 2X Long NVO ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"2倍做多NVO ETF-Defiance,NVOX,2倍做多NVO ETF-Defiance股票,2倍做多NVO ETF-Defiance股票老虎,2倍做多NVO ETF-Defiance股票老虎国际,2倍做多NVO ETF-Defiance行情,2倍做多NVO ETF-Defiance股票行情,2倍做多NVO ETF-Defiance股价,2倍做多NVO ETF-Defiance股市,2倍做多NVO ETF-Defiance股票价格,2倍做多NVO ETF-Defiance股票交易,2倍做多NVO ETF-Defiance股票购买,2倍做多NVO ETF-Defiance股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"2倍做多NVO ETF-Defiance(NVOX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供2倍做多NVO ETF-Defiance(NVOX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}